Edwards Lifesciences Co. (NYSE:EW) Holdings Lifted by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. raised its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 46.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,223,893 shares of the medical research company's stock after buying an additional 389,141 shares during the period. Adage Capital Partners GP L.L.C. owned approximately 0.21% of Edwards Lifesciences worth $90,605,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Abacus Planning Group Inc. increased its stake in shares of Edwards Lifesciences by 0.3% during the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company's stock worth $2,977,000 after purchasing an additional 140 shares in the last quarter. Bowman & Co S.C. increased its stake in shares of Edwards Lifesciences by 1.2% during the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company's stock worth $924,000 after purchasing an additional 148 shares in the last quarter. Moors & Cabot Inc. increased its stake in shares of Edwards Lifesciences by 0.3% during the 4th quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company's stock worth $4,041,000 after purchasing an additional 152 shares in the last quarter. Quadrant Capital Group LLC increased its stake in shares of Edwards Lifesciences by 3.1% during the 4th quarter. Quadrant Capital Group LLC now owns 5,180 shares of the medical research company's stock worth $383,000 after purchasing an additional 156 shares in the last quarter. Finally, Pegasus Asset Management Inc. increased its stake in shares of Edwards Lifesciences by 0.4% during the 4th quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company's stock worth $3,156,000 after purchasing an additional 159 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the transaction, the vice president now directly owns 22,588 shares in the company, valued at $1,569,414.24. The trade was a 1.74 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the transaction, the chief executive officer now owns 59,083 shares in the company, valued at $4,106,859.33. This represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,853 shares of company stock valued at $5,163,062. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Up 0.5 %

Edwards Lifesciences stock traded up $0.41 during midday trading on Tuesday, hitting $75.95. 1,407,141 shares of the stock were exchanged, compared to its average volume of 4,976,382. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The firm has a market cap of $44.65 billion, a P/E ratio of 10.89, a P/E/G ratio of 4.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a 50 day moving average price of $70.96 and a two-hundred day moving average price of $71.16.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. During the same period last year, the firm earned $0.66 earnings per share. The company's revenue for the quarter was up 6.2% compared to the same quarter last year. On average, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on EW shares. Robert W. Baird raised their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research report on Thursday, April 24th. Truist Financial decreased their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Morgan Stanley raised their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and raised their target price for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $85.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $79.45.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.